Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Instagram Outage Disrupts Thousands of U.S. Users 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2017 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced that preclinical results will be presented at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference will take place October 26-30 in Philadelphia.
Abstract Information:
| Title: | EGFR-CD3 bispecific Probody therapeutic induces tumor regressions and increases maximum tolerated dose >60 fold in preclinical studies |
| Session Category: | EGFR/Her2 |
| Date: | Saturday, October 28 |
| Time: | Poster Session A: 12:30 p.m. – 4:00 p.m. |
| Location: | Hall E, Pennsylvania Convention Center |
| Abstract: | A164 |
The EGFR-CD3 bispecific Probody therapeutic poster will also be included in the Spotlight on Proffered Papers session starting at 10:50 a.m. on Friday, October 27 in the Terrance Ballroom, 400 level.
| Title: | Optimizing a CD71-targeting Probody drug conjugate (PDC) for activity in multiple solid tumor and lymphoma models and for tolerability in nonhuman primates |
| Session Category: | Therapeutic Agents: Biological |
| Date: | Sunday, October 29 |
| Time: | Poster Session B: 12:30 p.m. – 4:00 p.m. |
| Location: | Hall E, Pennsylvania Convention Center |
| Abstract: | B116 |
| Title: | A multi-analyte HPLC-MS/MS approach to assessing exposure of a Probody drug conjugate (PDC) in preclinical studies |
| Session Category: | Therapeutic Agents: Biological |
| Date: | Sunday, October 29 |
| Time: | Poster Session B: 12:30 p.m. – 4:00 p.m. |
| Location: | Hall E, Pennsylvania Convention Center |
| Abstract: | B103 |
| Title: | Nonclinical safety evaluation of two distinct second generation variants of anti-CTLA4 monoclonal antibody, ipilimumab, in monkeys |
| Session Category: | Therapeutic Agents: Biological |
| Date: | Sunday, October 29 |
| Time: | Poster Session B: 12:30 p.m. – 4:00 p.m. |
| Location: | Hall E, Pennsylvania Convention Center |
| Abstract: | LB-B33 |
About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of Probody™ therapeutics. Probody therapeutics exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1 and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson Cancer Center and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on Twitter.
Media Contact:
Spectrum
Amir Khan
[email protected]
212-899-9730
Investor Contact:
Trout Group
Pete Rahmer
[email protected]
646-378-2973
